COMP <GO>
NVCR vs UNH // PIOTROSKI F-SCORE QUALITY
NovoCure Limited (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: NVCR 1
— UNH 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: UNH
LAST: $13.15 (+0.31%) • MKT CAP: $1.53B
piotroski-score
6/9
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVCR VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVCR | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.50% | 88.57% | -14.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.50% | 11.47% | -38.97 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.96% | 6.48% | -11.44 | UNH | /fcf-yield <GO> |
| Operating Margin | -23.50% | 4.82% | -28.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -20.80% | 3.14% | -23.94 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 8.30% | 6.46% | +1.84 | NVCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.54 | 3.12 | -2.58 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.8 | 59.2 | -25.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.53B | $368.83B | -$367.30B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVCR REV | UNH REV | NVCR GROSS % | UNH GROSS % | NVCR FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $655.4M | $447.57B | 74.5% | 88.7% | -$75.7M | $16.07B |
| FY 2024 | $605.2M | $400.28B | 77.3% | 88.3% | -$69.2M | $20.70B |
| FY 2023 | $509.3M | $371.62B | — | 89.6% | -$73.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVCR // BETA —
UNH // BETA 0.33